Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > CombiMatrix Receives New Contract From U.S. Department of Defense

Abstract:
Work On This Contract From Defense Advanced Research Projects Agency Could Enable New Military and Commercial Applications of CombiMatrix Technology and Products

CombiMatrix Receives New Contract From U.S. Department of Defense

MUKILTEO, WA | Posted on August 5th, 2008

CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has received a new contract from the Defense Advanced Research Projects Agency (DARPA) to initiate a new program utilizing its array technology and ElectraSense(r) reader. This program is focused on the development of a new application of CombiMatrix's microarray technology and involves the synthesis of molecules known as "aptamers," which are molecules with unique biological properties. Synthesis of aptamers followed by iterative evolution of these molecules, coupled with CombiMatrix's electrochemical-detection techniques, could enable powerful, label-free detection systems that could revolutionize analysis applications such as diagnostics, chemical measurement, biological and chemical agent detection, and others.

CombiMatrix's technologies are ideally suited for this type of work and the corresponding applications because of the ease with which customized molecules can be synthesized, and re-synthesized with necessary modifications, and the use of electrochemical measurement techniques pioneered by the company. Other array technologies do not have the functional capabilities of CombiMatrix's technology platform. The amount of the grant for this proof-of-concept study is $250,000.

"This funding will allow us to explore largely uncharted capabilities and applications that are inherent in our core technologies," stated Dr. David Danley, Director, Homeland Security and Defense Programs at CombiMatrix. "This seed funding will support a proof-of-concept demonstration of our capabilities. If successful, we will be seeking larger amounts of funding for continued development for this brand-new application of our technology."

"We are pleased that DARPA is supporting this research, as it may enable a whole series of new grants and contracts from the government," noted Dr. Amit Kumar, President and CEO of CombiMatrix. "While there are specific military needs and goals associated with this contract, the success of this program will enable commercial non-military applications and products addressing markets such as diagnostics, chemical sensing, analytics, and others. We hope this initial funding will lead to additional contracts and an additional portfolio of products for military and commercial markets."

####

About CombiMatrix Corporation
We are a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. We have also developed the capabilities of producing arrays that utilize bacterial artificial chromosomes on our arrays, also enabling genetic analysis. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985 CBMX (2269). Additional information about our laboratory, CombiMatrix Molecular Diagnostics, is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory, and competitive developments, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
CombiMatrix Corporation
Amit Kumar, Ph.D., President & CEO
(425) 493-2000
Fax: (425) 493-2010

Copyright © PrimeNewswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Shedding light on perovskite hydrides using a new deposition technique: Researchers develop a methodology to grow single-crystal perovskite hydrides, enabling accurate hydride conductivity measurements May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Govt.-Legislation/Regulation/Funding/Policy

International research team uses wavefunction matching to solve quantum many-body problems: New approach makes calculations with realistic interactions possible May 17th, 2024

Aston University researcher receives £1 million grant to revolutionize miniature optical devices May 17th, 2024

NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024

Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024

Announcements

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Finding quantum order in chaos May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Military

NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

New chip opens door to AI computing at light speed February 16th, 2024

New-Contracts/Sales/Customers

Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020

GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project